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106Management of acute limb ischemia in the pediatric
population
Ahmed Kayssi, MD, MS,a Furqan Shaikh, MD, MS,b Graham Roche-Nagle, MD, MBA,a
Leonardo R. Brandao, MD, MS,b Suzan A. Williams, MD,b and Barry B. Rubin, MD, PhD,a Toronto,
Ontario, Canada
Objective: Acute limb ischemia (ALI) in pediatric patients is rare but may lead to limb loss and life-long complications.
This study reviewed the experience of a Canadian tertiary pediatric center with the medical and operative management
of ALI.
Methods: The medical records of inpatients diagnosed with ALI of the upper or lower limb between 1999 and 2012 were
reviewed. Patient demographics, arterial clot site and etiology, intervention, anticoagulation type and duration, and
short-term and long-term complications were analyzed.
Results: A total of 151 patients (45% female) presented with signs of limb ischemia, of whom 38% were aged <30 days,
46% were between 1 and 12 months, and 16% were between 1 and 18 years. Ninety-four percent of those injuries involved
the lower limbs. Ninety-one percent were due to vessel catheterization, 5% were idiopathic, 1% were congenital, and 4%
traumatic. Ninety-four percent were managed nonoperatively. Patients were treated with a combination of thrombolysis,
unfractionated or low-molecular-weight heparin, aspirin or warfarin, or both (duration, 1 day-13 years). All patients were
monitored after discharge at our institution or at their referring hospital (average, 3.4 6 2.8 years). Fifteen percent had
complications related to ALI or anticoagulation (most commonly limb length or thigh circumference discrepancy, or
intracranial hemorrhage). Nineteen percent of patients died of unrelated causes (sepsis, multiorgan dysfunction, or
cardiac failure).
Conclusions: In contrast with adults, ALI in children can generally be managed nonoperatively with anticoagulation, likely
because of their greater ability to develop arterial collaterals. Long-term follow-up by a multidisciplinary team of pediatric
and surgical specialists and allied health professionals is integral to achieving a successful outcome in children with ALI.
(J Vasc Surg 2014;60:106-10.)Acute limb ischemia (ALI) is a potentially catastrophic
event that can lead to death of nerve and then muscle tissue
within 4 to 6 hours unless the limb is revascularized.1 In
cases of incomplete ischemia, in which there is no evidence
of tissue loss or postischemic neuromuscular deﬁcits, a trial
of nonoperative management can be attempted.2 ALI is an
infrequent but potentially devastating condition in the pe-
diatric population. It is usually post-traumatic or iatrogenic
and is rarely secondary to arterial occlusive disease as in the
adult population. Previous studies have demonstrated that
an initial trial of anticoagulation is safe and usually success-
ful when treating pediatric patients with ALI secondary to
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physicians and surgeons caring for those patients are usually
guided by consensus guidelines that mostly extrapolate
from the adult literature rather than from well-designed
prospective studies in the pediatric population.6 The aim
of this study was to review the experience of the Hospital
for Sick Children, Canada’s largest pediatric center, with
the medical and operative management of ALI in the pedi-
atric population.
METHODS
We reviewed the medical records of inpatients diag-
nosed with ALI of the upper or lower limb at the Hospital
for Sick Children in Toronto, Ontario, Canada, between the
years 1999 and 2012. The research protocol was approved
by the hospital’s Institutional Review Board. Medical re-
cords were identiﬁed by searching the hospital’s imaging
database using keywords suggestive of ALI. Keyword com-
binations used included “Arterial” and “Thrombus” and
“Arm”; “Arterial” and “Thrombus” and “Leg”; “Arterial”
and “Thrombus” and “Limb”; “Ischemic” and “Arm”;
“Ischemic” and “Leg”; “Ischemic” and “Limb”; “Trauma”
and “Ischemia”; and “Trauma” and “Thrombus.”
Individual patient records were then reviewed to iden-
tify patients with clinical evidence of ALI such as limb
pulselessness, poikilothermia, pallor, or tissue loss. Oper-
ative patients previously known to the thrombosis team
or the vascular surgery service (which is based at Toronto
General Hospital and consults on patients with vascular
Table I. Site of arterial pathology among 151 pediatric
patients with acute limb ischemia (ALI)
Site of arterial pathology Patients, No. (%)
Lower extremity 142 (94)
External iliac 64 (42)
Common femoral 46 (30)
Superﬁcial femoral 16 (11)
Common iliac 12 (8)
Popliteal 3 (2)
Internal iliac 1 (1)
Upper extremity 9 (6)
Brachial 4 (3)
Axillary 2 (1)
Subclavian 2 (1)
Ulnar 1 (1)
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captured in the imaging database search were also
included in the analysis. Patient demographics, arterial
clot site and etiology, type of intervention, type and dura-
tion of anticoagulation, and short-term and long-term
complications were analyzed. Descriptive statistics were
generated using Excel 2010 software (Microsoft Corp,
Redmond, Wash).
RESULTS
Demographics. The imaging database search identi-
ﬁed 1553 patient charts. Of these, 151 patients with radio-
logic evidence of upper or lower limb arterial disease and
clinical signs of limb ischemia were subsequently identiﬁed
after a detailed record review. Eighty-three of 151 patients
(55%) were boys. Patients were an average age of 1.51 6
3.72 years, with 57 (38%) #30 days old, 70 (46%) 1 to
12 months old, and 24 (16%) >1 year old.
Mechanism and site of injury. Injuries in 137 pa-
tients (91%) were iatrogenic secondary to catheterization
mostly for cardiac indications. Other signiﬁcant contribu-
tors to the thrombotic events were idiopathic in eight pa-
tients (5%), congenital secondary to popliteal artery
entrapment syndrome or prothrombin gene mutation in
two (1%), or traumatic in four (3%). Most injuries occurred
in the lower extremity (142 patients [94%]) and included
the external iliac (64 patients [42%]) or common femoral
(46 patients [30%]) arteries (Table I).
Treatment of patients with iatrogenic ALI. All pa-
tients with a clinical and radiologic diagnosis of iatrogenic
ALI were started on intravenous unfractionated or subcu-
taneous low-molecular-weight heparin (LMWH) therapy
at therapeutic weight-based doses, except in two patients
with evidence of intracranial hemorrhage. Although 129 of
the patients with postcatheterization ALI (94%) were
treated with anticoagulation alone, eight patients (6%)
showed no clinical improvement after 24 hours of anti-
coagulation therapy and received a course of tissue plas-
minogen activator (tPA). The tPA was administered
systemically to seven patients (5%), whose ages ranged
between 7 days and 7 years. Catheter-directed thrombol-
ysis was administered to the remaining patient, who was
17 years old.
Five patients (4%) responded favorably to tPA treat-
ment and demonstrated evidence of clinical improvement
or resolution of the clot by ultrasound. The remaining 3
patients (2%) underwent thrombectomy, fasciotomy, or
an amputation in the operating room (Table II). One pa-
tient with a failed Fontan procedure and subsequent post-
catheterization limb ischemia was too hemodynamically
unstable to receive tPA and was prepared for an embolec-
tomy procedure, but died of cardiopulmonary failure en
route to the operating room before undergoing surgery.
Treatment of patients with other causes of ALI.
ALI in 14 patients (9%) was secondary to noniatrogenic
causes, of whom three patients (21%) sustained blunt or
penetrating trauma and were taken to the operating
room immediately (Table II). The remaining 11 patientswere given a trial of anticoagulation therapy. Eight of the
11 patients (73%) had idiopathic causes of ALI for which
no clear etiology was identiﬁed. Six of the idiopathic ALI
patients (75%) resolved with anticoagulation therapy
alone (including an 11-year-old patient who received
systemic tPA therapy). The remaining two patients
required surgery after developing clinical signs of pro-
gressive tissue ischemia while receiving anticoagulation
therapy (Table II).
Three patients (2%) had evidence of popliteal artery
entrapment, prothrombin gene mutation, and antiphos-
pholipid antibody syndrome, and two underwent opera-
tions after a course of anticoagulation (Table II). The
patient with the antiphospholipid antibody syndrome
died subsequent to multiple hemorrhagic strokes unrelated
to the management of her ALI and did not undergo
surgery.
Anticoagulation. The hospital’s thrombosis service,
which comprises hematology staff physicians, clinical
fellows, and nurses, monitored 137 patients (91%) for
the management of their anticoagulation. The remaining
patients’ anticoagulation therapy was managed indepen-
dently by their admitting service (eg, cardiology). Antico-
agulation was continued until there was clinical and
radiologic evidence of clot resolution. The duration of
anticoagulation with unfractionated heparin, LMWH,
warfarin, or aspirin was a mean of 2.5 6 3.9 months
(range, 1 day-18 years; median, 1.5 months; mode,
3 months) depending on coexistent conditions requiring
prolonged anticoagulation (eg, deep vein thrombosis,
dilated cardiomyopathy, Fontan procedure, mechanical
heart valves).
Follow-up. The thrombosis team or the vascular sur-
gery service followed up 85 patients (56%) as outpatients
for an average duration of 3.4 6 2.8 years. The remain-
ing 66 patients (44%) resumed their care at their refer-
ring hospital, did not return to scheduled follow-up
visits at our institution, or died of unrelated causes in
the hospital.
Thrombophilia testing. Of the patients who were fol-
lowed up in our institution’s thrombosis clinic, 46 (54%)
were tested for a heritable thrombophilia, and nine (20%)
Table II. Clinical proﬁle, operation type, and postoperative complications among 10 pediatric patients who required
surgical intervention for acute limb ischemia (ALI)a
Pt Clinical history Operation Complications
1 1-day-old boy: protein C deﬁciency
born with axillary artery thrombosis
Thrombectomy with a size 2 Fogerty
catheter; miscrosurgical closure of
the arteriotomy by cardiac and plastic
surgery team
Uncomplicated recovery
2 13-year-old girl: idiopathic common
femoral artery thrombosis
Thrombectomy after failed heparin
therapy
Uncomplicated recovery
3 7-year-old girl: postcatheterization
brachial artery thrombosis and
ischemic forearm
Thrombectomy after failed systemic
tPA therapy
Progressive ischemia, right below
elbow amputation
4 17-year-old girl: intravenous drug user
with right popliteal artery embolism
Thrombectomy after failed catheter-
directed tPA therapy
Compartment syndrome, right below-
knee amputation
5 13-year-old boy: open dislocation right
knee with transection of popliteal
artery and vein
Femoropopliteal bypass with
contralateral reversed great
saphenous vein
Compartment syndrome, pes cavus
6 10-year-old girl: impalement of left
thigh with ski pole with SFA and FV
transection
SFA and FV reconstruction with
contralateral reversed great
saphenous vein
Post-op thigh hematoma evacuated
surgically
7 13-year-old boy: post-traumatic
brachial artery laceration
Bypass vein graft Ulnar nerve compression
8 11-month-old boy: Potter syndrome
and postcatheterization leg ischemia
4-compartment fasciotomies after failed
systemic tPA therapy
Died of multiorgan dysfunction
9 12-year-old girl: type I popliteal artery
entrapment syndrome and
gangrenous toe
Popliteal artery decompression Uncomplicated recovery
10 1 day-old boy: right axillary artery
thrombosis and below-elbow
ischemia
Right above-elbow amputation Brachial artery thrombosis and stump
revision
FV, Femoral vein; SFA, superﬁcial femoral artery; tPA, tissue plasminogen activator.
aDetails for one patient, who died en route to the operating room, are not included.
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included factor V Leiden in 4 patients (9%), protein C deﬁ-
ciency in 2 (4%), and protein S deﬁciency in 1 (2%). Two
patients (5%) tested positive for anticardiolipin antibodies
and were diagnosed with antiphospholipid antibody
syndrome.
Complications. Twenty-nine patients (19%) died of
causes that were not directly related to limb ischemia
such as cardiopulmonary failure or multiple organ
dysfunction. Of the patients followed up as outpatients,
13 (15%) developed claudication or limb length or limb
circumference discrepancy. A signiﬁcant bleeding episode
occurred in four patients who were treated with anticoa-
gulation on diagnosis of ALI (3%), consisting of two pa-
tients with nonfatal intracranial hemorrhages while
receiving LMWH, one postoperative thigh hematoma
requiring surgical incision and drainage while receiving
LMWH, and one groin hematoma while receiving tPA
that was managed nonoperatively.
Concurrent venous thrombosis. Fifty-nine patients
(39%) had concurrent venous thrombosis. All of those pa-
tients had a history of central venous access to the affected
limb during their hospitalization. The venous thrombosis
was managed with anticoagulation alone. Of these patients,
24% died in the hospital and 17% developed long-term
complications such as discrepancy in limb or thigh circum-
ference (7%), signiﬁcant anticoagulation-related bleeding
(5%), or amputation (3%). Two of those patients (3%) testedpositive for anticardiolipin antibodies or factor V Leiden
during outpatient follow-up.
DISCUSSION
This study describes a single-institution experience
with the clinical and operative management of ALI in pedi-
atric patients during a 13-year interval. Although most of
the patients in our series were newborns and infants
aged <12 months, there was no signiﬁcant variability in
evaluation, management, or outcomes between those pa-
tients and older children. Our ﬁndings suggest that ALI
in pediatric patients, in contrast to adults, can generally
be managed successfully with anticoagulation. This is likely
because neonates and children differ from adults in physi-
ology, pharmacologic responses to anticoagulation, epide-
miology, and long-term consequences of thrombosis, as
well as in an enhanced ability to form a collateral vascular
supply to the limbs.6
In the absence of data from prospective trials, the
timing of an operation for ALI in pediatric patients varies
by institution. No speciﬁc guidelines exist for the use of
thrombectomy in children, but the general consensus is
that the recurrence rate and risk of long-term vascular dam-
age is high.6 At our center, patients with clinical evidence
of limb ischemia, such as pulselessness or poikilothermia,
and radiologic evidence of absent blood ﬂow in the affected
limb, and who had no contraindications were given a 24-
hour trial of anticoagulation of unfractionated heparin or
JOURNAL OF VASCULAR SURGERY
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at the time of presentation with ALI. Those who showed
no clinical or radiologic evidence of clot resolution after
24 hours were considered for a trial of thrombolysis using
tPA. If the tPA therapy failed, patients were then offered a
surgical intervention.
The duration of anticoagulation in pediatric ALI is also
subject to consensus guidelines rather than prospective
data. Current guidelines recommend a 5- to 7-day course
of therapeutic anticoagulation with unfractionated heparin
or LMWH for neonates or children with acute femoral ar-
tery thrombosis (level of evidence: 2C).6 There are no
guidelines, however, for the management of thrombosis
in other arteries or in patients who demonstrate clinical
improvement but lack of clot resolution on Doppler ultra-
sound imaging, high-risk patients with a history of clotting
disorders, or patients with concurrent asymptomatic
venous thrombosis. As such, anticoagulation therapy was
continued in many of our patients for 6 weeks to 3 months,
until there was evidence of clot resolution on imaging. Pa-
tients who were discharged from the hospital were then fol-
lowed up as outpatients at our hospital or at their referring
center for evidence of arterial insufﬁciency. None of the pa-
tients in our series underwent a surgical intervention due to
long-term sequelae of arterial insufﬁciency.
In our series, patients who presented to the emergency
department with ALI secondary to blunt or penetrating
trauma and arterial injury underwent immediate bypass sur-
gery. In all instances, a native reversed vein graft harvested
from the contralateral lower extremity was used to perform
the bypass. There is evidence for an excellent outcome with
this approach, with minimal graft dilation or stenosis on
long-term follow-up in children.7-9
The testing of pediatric patients with ALI for underly-
ing hypercoagulable states is a topic of controversy. All pa-
tients presenting for outpatient follow-up at our institution
were offered a hypercoagulable workup, and 54% con-
sented to undergo this assessment. However, the current
treatment guidelines for ALI are indifferent to whether a
pediatric patient has a heritable hypercoagulable state.6
Moreover, such blood tests are costly and may have impli-
cations regarding the ability of patients and their families to
obtain health insurance.
Functional protein assay tests for protein C, protein S,
or antithrombin may also be inaccurate in patients who are
on existing anticoagulation therapy or if ordered at the
time of an acute thrombotic event. For example, a recent
audit by a pediatric center in New Zealand demonstrated
that only 37% of tests with abnormal results were repeated
for conﬁrmation of conditions such as antithrombin and
proteins C or S deﬁciency, despite evidence that such diag-
noses should not be made from a single set of results.10
Furthermore, current British guidelines only recommend
protein C and S deﬁciency testing in neonates with pur-
pura fulminans (level of evidence: 1B). These guidelines
do not recommend a hypercoagulable workup in patients
with arterial thrombosis (level of evidence: 1B) or inasymptomatic relatives with low-risk thrombophilia (level
of evidence: 1B).11
Given that only 20% of the patients that we investi-
gated were identiﬁed as having a hypercoagulable state
and that this ﬁnding did not change their immediate or
long-term management, the utility of thrombophilia
testing may be quite limited. Certainly, thrombophilia
testing would not appear to have any beneﬁt in patients
with an iatrogenic injury with a clearly identiﬁed risk factor.
However, in children with idiopathic arterial thrombosis,
there would be a potential for a hypercoagulable state to
have an effect on long-term management, and therefore,
testing might be an appropriate consideration.
Our study is limited for a number of reasons. Firstly, it
is a retrospective review of patients principally identiﬁed
through a search of an imaging database that may not
have captured all of the patients meeting our predeﬁned in-
clusion criteria. Secondly, many of our patients were lost to
follow-up through death, relocating to another city, or not
presenting for scheduled clinic appointments. This, unfor-
tunately, limits our ability to completely characterize the
long-term complications in our patient population.
CONCLUSIONS
On the basis of our observations, we conclude that
management by a multidisciplinary team that includes
vascular surgeons, hematologists, medical imaging, and pe-
diatric intensive care physicians is necessary to achieve a
successful outcome in pediatric patients who present with
ALI and that conservative management with anticoagula-
tion will yield a good long-term result in most of these pa-
tients. The limitations with this study that we have
identiﬁed should be taken into account when evaluating
the conclusions of this review, which constitutes the largest
series reported to date on the management of ALI in pedi-
atric patients.
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Submitted Oct 31, 2013; accepted Jan 20, 2014.DISCUSSIONDr Peter Lawrence (Los Angeles, Calif). Would you address
the issue of the tiny patient who has unilateral limb ischemia and
a very small femoral artery? I noticed that there are very few in
that operative category. When do you explore the artery and
when do you use a microscope? What kind of catheters do you
use to extract the clot?
Dr Ahmed Kayssi. We had a 1-day-old patient in our series
who was born with a congenital abnormality requiring catheteriza-
tion. Unfortunately, he was taken to the operating room by our
colleagues in cardiac surgery, and we could not ﬁnd an operative
note in his chart; so, I can’t comment on the technical aspects of
that case.
Dr Lawrence. Is that because you avoid operating on babies
below a certain femoral artery size? What would be your approach
to the baby who still has an acutely ischemic limb after removal of
an umbilical artery catheter and has a tiny common femoral
artery?
Dr Kayssi. I don’t have the answer to that question. The
Hospital for Sick Children does not have a dedicated vascular sur-
gery service and so they call upon the vascular surgeons from across
the street at Toronto General Hospital to provide coverage on an
as-needed basis. I don’t know what my colleagues’ operative
approach to a neonate would be.
Dr Linda Harris (Buffalo, NY). Do you differentiate your
plans for intervention based on whether they are traumatic or iat-
rogenic? What do you use as your indication for intervention? I
would agree with anticoagulation, especially in the very young chil-
dren. Is there an age at which you would say you go to the oper-
ating room sooner or intervene sooner? Obviously, the young
infants have very tiny vessels and don’t respond as well to surgical
interventions, but what if you have a 10-year-old or a 12-year-old,
are you faster to the operating room?
Dr Kayssi. There is no difference in our management proto-
col according to age. Our treatment protocol is based on giving
the patient a trial of anticoagulation ﬁrst with unfractionated or
low-molecular-weight heparin, unless there is obvious evidenceof tissue loss, in which case those patients are taken to the oper-
ating room immediately.
If at 24 hours there is no clinical or ultrasound evidence of clot
resolution, than a course of tissue plasminogen activator would be
considered, unless contraindicated. In our nine patients who
received tPA, in seven instances the tPA course was successful.
Two patients, however, did require an operative intervention after
failing tPA.
Dr James Stanley (Ann Arbor, Mich). I have one question
and one admonition. The fact that approximately a third of your
patients were under the age of 30 days raises the question as to
whether these children developed their limb ischemia as a conse-
quence of an umbilical artery catheterization that became a focus
of a thrombotic or embolic event. My speciﬁc question relates to
what percentage of neonates undergoing umbilical catheterization
at the Hospital for Sick Children develop altered lower extremity
blood ﬂow, be it symptomatic or not. The frequency of this
even has been poorly documented in the literature.
Dr Kayssi. That’s a great question, sir. We did not look for
that in the data set.
Dr Stanley. Many infants and young children with acute cath-
eter-based external iliac or femoral arterial occlusions develop robust
collaterals to the affected extremity. In fact, they often have easily
palpable distal pulses, may have normal resting ankle-brachial
indices, and some do not have an exercise-related drop in their
ankle-brachial index because of the very minimal resistance in these
large collateral channels. Unfortunately, as the child becomes older,
the affected limb may exhibit long-bone growth retardation. If the
ensuing limb-length discrepancy goes unrecognized and untreated,
the outcome may be very disabling. This subject was addressed
2 days ago at this meeting when we presented the University of
Michigan’s recent experience with 28 preadolescent children having
lower extremity ischemia that required operative intervention. My
admonition is that many pediatric patients with acute limb ischemia
need careful long-term follow-up if chronic problems are to be
avoided. Their initial management is only a part of their care.
